Mount Tam Biotechnologies, which is based at and partners with the Buck Institute for Research on Aging, has appointed Jim Stapleton as CFO. Mr. Stapleton succeeds current interim CFO David R. Wells. Richard Marshak, Chief Executive Officer of Mount Tam, said, “We are excited to bring Jim on board given his impressive background and track record of success. With Jim as CFO we will be focusing on strengthening our financial position to assure that we can fully leverage the Mount Tam IP portfolio and move forward with the exciting clinical opportunities that we are pursuing in mTOR modulation. I also want to take this opportunity to thank David Wells for his contributions to Mount Tam as interim CFO, and to wish him the best in his future endeavors at Wells Compliance Group.”
For more information, visit the Mount Tam Biotechnologies website.